



LEI: 549300Q7EXQQH6KF7Z84

14 August 2024

RTW Biotech Opportunities Ltd
(the "Company")

Closed Period Notification

Compliance with the Market Abuse Regulation (MAR)

The Company announces that it is satisfied that all inside information which the directors and the Company may have in the period leading up to the announcement of the Half-Year Report for the six months ended 30 June 2024 has been notified to a Regulated Information Service (RIS). The Company is therefore not prohibited from purchasing its own securities or issuing shares during the closed period (as defined by MAR) which ends on the date of the announcement of the Half-Year Report.

If, in the period leading up to the announcement of the Half-Year Report, the directors of the Company come into possession of any inside information, this will be notified to a RIS before any such transactions are undertaken.

The closed period will last until the Half-Year Report in respect of the six months ended 30 June 2024 is published, which is expected to be on or around 13 September 2024.

For Further Information:

RTW Investments, LP
Woody Stileman, Managing Director
Krisha McCune, Director, Investor Relations

+44 (0)20 7959 6361

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCQKNBDQBKDCFD